Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine

NCT02114060 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

310

Enrollment

INDUSTRY

Sponsor class

Conditions

Genital Herpes Simplex Type 2

Interventions

BIOLOGICAL: GEN-003 Vaccine (30μg of each antigen)
BIOLOGICAL: GEN-003 Vaccine (60μg of each antigen)
BIOLOGICAL: Matrix-M2 Adjuvant (25μg)
BIOLOGICAL: Matrix-M2 Adjuvant (50μg)
BIOLOGICAL: Matrix-M2 Adjuvant (75μg)
BIOLOGICAL: Placebo

Sponsor

Genocea Biosciences, Inc.